The German company will use funding to commercialise its enzyme platform for the industrial use of biomass residues, supporting more circular and sustainable chemical value chains.
Munich-based Twogee Biotech, a biotechnology start-up developing customised enzyme solutions for the industrial conversion of biomass into sustainable raw materials, has completed a €2.16 million seed financing round. The round includes investments from High-Tech Gründerfonds and Bayern Kapital, as well as strategic partners AgriFoodTech Venture Alliance and Heinz Entsorgung.
Founded in 2024 by Frank Wallrapp and Helge Jochens, Twogee Biotech supports industrial partners in converting low-value biomass residues and by-products into sustainable second-generation raw materials, with a focus on sugars for bio- and synthetic biology applications.
The company’s approach is based on a predictive development platform that integrates enzyme screening, strain engineering, and fermentation. This enables more efficient biomass utilisation while helping industrial partners advance circular, low-CO₂ value creation by shortening development timelines and reducing scale-up risk.
Frank Wallrapp, CEO of Twogee Biotech, said that many industrial residual streams contain untapped economic potential and that the company supports partners in accessing this value through solutions designed for straightforward integration and clear commercial benefits.
The company plans to use the newly raised capital to further develop its technology and advance commercialisation. Initial MVPs and paid pilot projects with industrial partners have already been completed.
Twogee Biotech intends to pursue a licensing model that enables local enzyme production at customer sites, with the aim of reducing costs and emissions while supporting decentralised, circular value chains.